IRIS
CAZZOLA, MARIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 10.758
EU - Europa 7.569
AS - Asia 5.696
SA - Sud America 35
Continente sconosciuto - Info sul continente non disponibili 27
AF - Africa 26
OC - Oceania 19
Totale 24.130
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.644
CN - Cina 5.138
IE - Irlanda 2.216
UA - Ucraina 1.539
FI - Finlandia 1.110
DE - Germania 839
SE - Svezia 710
IT - Italia 550
SG - Singapore 431
GB - Regno Unito 333
FR - Francia 123
CA - Canada 100
RU - Federazione Russa 46
IN - India 39
BE - Belgio 34
IR - Iran 22
NL - Olanda 22
EU - Europa 20
JP - Giappone 20
AU - Australia 18
MU - Mauritius 17
HK - Hong Kong 12
BR - Brasile 10
PA - Panama 10
CZ - Repubblica Ceca 9
BO - Bolivia 8
CL - Cile 8
RO - Romania 7
TR - Turchia 7
A2 - ???statistics.table.value.countryCode.A2??? 5
LT - Lituania 5
PL - Polonia 5
AT - Austria 4
CO - Colombia 4
LV - Lettonia 4
ZA - Sudafrica 4
BD - Bangladesh 3
CH - Svizzera 3
ES - Italia 3
KR - Corea 3
LA - Repubblica Popolare Democratica del Laos 3
MX - Messico 3
NG - Nigeria 3
AZ - Azerbaigian 2
BG - Bulgaria 2
DK - Danimarca 2
EG - Egitto 2
IL - Israele 2
MN - Mongolia 2
PE - Perù 2
TW - Taiwan 2
VN - Vietnam 2
XK - ???statistics.table.value.countryCode.XK??? 2
AR - Argentina 1
CR - Costa Rica 1
EC - Ecuador 1
FK - Isole Falkland (Malvinas) 1
GE - Georgia 1
HU - Ungheria 1
ID - Indonesia 1
IQ - Iraq 1
JO - Giordania 1
KZ - Kazakistan 1
LK - Sri Lanka 1
MY - Malesia 1
NZ - Nuova Zelanda 1
QA - Qatar 1
RS - Serbia 1
SK - Slovacchia (Repubblica Slovacca) 1
Totale 24.130
Salva come PNG Salva come JPEG
Città #
Chandler 2.220
Dublin 2.213
Jacksonville 1.998
Nanjing 1.554
Boardman 781
Ashburn 704
Nanchang 614
Princeton 517
Lawrence 496
Wilmington 489
Hebei 462
Shenyang 454
Changsha 395
Jiaxing 372
Medford 350
Singapore 303
Beijing 278
Helsinki 253
Hangzhou 240
Tianjin 227
Ann Arbor 206
New York 134
Milan 132
Woodbridge 110
Shanghai 101
Norwalk 96
Toronto 78
Verona 76
Pavia 69
Seattle 65
Falls Church 54
Jinan 52
Los Angeles 44
Fairfield 42
Kunming 38
Washington 38
Des Moines 37
Zhengzhou 35
Brussels 34
Ningbo 33
Houston 30
Taizhou 28
Chicago 26
Guangzhou 25
Tappahannock 21
Auburn Hills 17
Rome 17
Falkenstein 14
Tokyo 14
Dearborn 13
Lanzhou 13
San Francisco 13
Borås 12
Fuzhou 12
Pune 12
Redwood City 12
Florence 11
Munich 11
Ottawa 10
Panama City 9
Goiânia 8
La Paz 8
Leawood 8
Changchun 7
Dallas 7
Haikou 7
Naples 7
Frankfurt am Main 6
Kemerovo 6
London 6
Melbourne 6
Orange 6
Paris 6
Monmouth Junction 5
Novokuznetsk 5
Santa Clara 5
Trento 5
Ardabil 4
Brignano Gera D'adda 4
Brno 4
Fayetteville 4
Gallarate 4
Hong Kong 4
Manchester 4
Montecchio Emilia 4
Montespertoli 4
Napoli 4
Reston 4
Zanjan 4
Andover 3
Bari 3
Bovisio Masciago 3
Canberra 3
Catania 3
Chongqing 3
Delhi 3
Forest City 3
Isfahan 3
Kowloon City 3
Langfang 3
Totale 16.903
Salva come PNG Salva come JPEG
Nome #
A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis 96
Anemia associata ad endocrinopatie. 94
WALDENSTROM'S HYPERGLOBULINEMIC PURPURA IN HLA IDENTICAL SISTERS. 92
Familial-skewed X-chromosome inactivation as a predisposing factor for late-onset X-linked sideroblastic anemia in carrier females. 91
Inhibition of c-ABL expression in hematopoietic progenitor cells using antisense oligodeoxynucleotides 89
Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts 88
A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. 85
Cord blood-derived hematopoietic progenitor cells: in vitro response to hematopoietic growth factors and their recruitment into the S-phase of the cell cycle. 85
Biological and clinical relevance of matrix metalloproteinases 2 and 9 in acute myeloid leukaemias and myelodysplastic syndromes. 83
A case of persistent eosinophilia 82
Further concerns about the medical risks of blood doping. 81
Blood p50 evaluation enhances diagnostic definition of isolated erythrocytosis. 81
Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndrome 80
Bone marrow microvessel density in chronic myeloproliferative disorders: a study of 115 patients with clinicopathological and molecular correlations 80
Hereditary hyperferritinemia-cataract syndrome: relationship between phenotypes and specific mutations in the iron-responsive element of ferritin light-chain mRNA. 79
Blast phase of essential thrombocythemia: A single center study. 78
Microcytic anemia in rheumatoid arthritis. Relationship with activity and duration of the disease and iron status. 78
ANALYSIS OF THE MITOCHONDRIAL FERRITIN PHYSIOPATHOLOGICAL ROLE IN SIDEROBLASTIC ERYTHROPOIESIS 78
USE OF A MONOCLONAL ANTIBODY AGAINST HUMAN HEART FERRITIN FOR EVALUATING ACIDIC FERRITIN CONCENTRATION IN HUMAN SERUM 77
Circulating endothelial cell separation from peripheral blood of patients affected by myelodysplastic syndromes: Preliminary results obtained by a new immunomagnetic procedure 77
Cytoreductive therapy for patients with essential thrombocythemia at high risk of thromboembolic complications. The difficult choice of the optimal drug 76
CALR exon 9 mutations are somatically acquired events in familial cases of essential thrombocythemia or primary myelofibrosis 76
A model for analysing the cost of autologous peripheral blood progenitor cell (PBPC) transplantation 74
Classification and prognostic evaluation of myelodysplastic syndromes 73
A prognostic model for predicting the impact of comorbidities on survival of patients with myelodysplastic syndromes 73
Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis 73
Not just clonal expansion of hematopoietic cells, but also activation of their progeny in the pathogenesis of myeloproliferative disorders 72
Clinical significance of neutrophil CD177 mRNA expression in Ph-negative chronic myeloproliferative disorders 72
Myelodysplastic syndromes are propagated by rare and distinct human cancer stem cells in vivo. 72
Tie2 expressing monocytes in the spleen of patients with primary myelofibrosis 72
Clinical severity and thermodynamic effects of iron-responsive element mutations in hereditary hyperferritinemia-cataract syndrome 71
JAK2 (V617F) mutation in healthy individuals 71
A mutation in the TMPRSS6 gene, encoding a transmembrane serine protease that suppresses hepcidin production, in familial iron deficiency anemia refractory to oral iron 71
Intracellular calcium deposits and store operated calcium entry in CD34+ cells from patients with myelofibrosis carrying a CALR mutation 71
Complex Patterns of Chromosome 11 Aberrations in Myeloid Malignancies Target CBL, MLL, DDB1 and LMO2. 71
A modified high-dose dexamethasone regimen for primary systemic amyloidosis 70
Clinical relevance of anemia and transfusion iron overload in myelodysplastic syndromes 70
Evidence for a polyclonal nature of the cell infiltrate in sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease). 70
Survivin expression, apoptosis and proliferation in chronic myelomonocytic leukemia 69
Gain of function, loss of control - a molecular basis for chronic myeloproliferative disorders 69
Pipobroman is safe and effective treatment for patients with essential thrombocythaemia at high risk of thrombosis 69
Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome. 69
Deferoxamine in thalassemia major. 68
VASCULAR ENDOTHELIAL GROWTH FACTOR OVEREXPRESSION IN BONE MARROW CELLS FROM PATIENTS WITH MYELODYSPLASTIC SYNDROME: BIOLOGICAL AND CLINICAL RELEVANCE 68
A screen for RAS mutations in individuals at risk of secondary leukaemia due to occupational exposure to petrochemicals. 68
Sequential administration of interleukin-3 and granulocyte-macrophage colony-stimulating factor following intensified, accelerated CEE (cyclophosphamide, epirubicin, etoposide) chemotherapy: cytokinetic effects on bone marrow hematopoietic progenitors. 67
Leukemia risk models in primary myelofibrosis: an International Working Group study. 67
Policitemia vera. 67
A translational link between Fe and Epo 67
MYD88 (L265P) mutation is an independent risk factor for progression in patients with IgM monoclonal gammopathy of undetermined significance 67
Blunted erythropoietin production and defective iron supply for erythropoiesis as major causes of anaemia in patients with chronic heart failure 67
Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms 67
Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia. 67
A linkage between hereditary hyperferritinaemia not related to iron overload and autosomal dominant congenital cataract. 66
Effect of recombinant gamma interferon on the proliferative activity of cultured leukemic cells. 66
Biologic and clinical significance of somatic mutations of SF3B1 in myeloid and lymphoid neoplasms 66
JAK inhibitor in CALR-mutant myelofibrosis 66
Once-weekly epoetin beta is highly effective in treating anaemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin production 66
Clinical significance of somatic mutation in unexplained blood cytopenia 66
Clinical effects of driver somatic mutations on the outcomes of patients with myelodysplastic syndromes treated with allogeneic hematopoietic stem-cell transplantation. 66
Italian Society of Hematology practice guidelines for the management of iron overload in thalassemia major and related disorders 65
Abnormal splenic uptake of red cells in long-lasting iron deficiency anemia due to self-induced bleeding (factitious anemia). 65
Effects of mitochondrial ferritin overexpression in normal and sideroblastic erythroid progenitors. 65
Somatic mutations of calreticulin in myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms. 65
Accelerated erythroid repopulation with no stem-cell competition effect in children treated with recombinant human erythropoietin after allogeneic bone marrow transplantation 65
Classification of anaemia on the basis of ferrokinetic parameters. 65
Tumor necrosis factor alpha down-regulates c-myc mRNA expression and induces in vitro monocytic differentiation in fresh blast cells from patients with acute myeloblastic leukemia. 65
Translational pathophysiology: a novel molecular mechanism of human disease 64
Busulfan, cyclophosphamide and melphalan as conditioning regimen for bone marrow transplantation in children with myelodysplastic syndromes 64
Effects of desferrrioxamine on normal and leukemic human hematopoietic cell growth: in vitro and in vivo studies 64
Haploinsufficiency of RPS14 in 5q− syndrome is associated with deregulation of ribosomal- and translation-related genes 64
The role of the JAK2 GGCC haplotype and the TET2 gene in familial myeloproliferative neoplasms. 64
Erythrokinetics and mechanisms of anaemia in hereditary elliptocytosis and hereditary ovalocytosis. 64
Ittero. 64
Clinical and biological implications of driver mutations in myelodysplastic syndromes 64
Hyperferritinemia-cataract syndrome associated to the HFE gene mutation. Two new Spanish families and a new mutation (A37T: "Zaragoza") 63
Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes 63
Natural history of juvenile haemochromatosis 63
Gene expression profiling of CD34+ cells in patients with the 5q- syndrome 63
Cell kinetics of CD34-positive hematopoietic cells following chemotherapy plus colony-stimulating factors in advanced breast cancer. 63
Basic and acidic isoferritins in the serum of patients with Hodgkin's disease. 63
A moderate transfusion regimen may reduce iron loading in beta-thalassemia major without producing excessive expansion of erythropoiesis. 63
X-linked Wiskott-Aldrich syndrome in a girl. 63
A chronic lymphoproliferative disorder 63
A WHO classification-based prognostic scoring system (WPSS) for predicting survival in myelodysplastic syndromes 63
Mitochondrial ferritin: a new player in iron metabolism 63
Myelodysplastic syndromes: recent advances 62
An atypical myeloproliferative disorder with high thrombotic risk and slow disease progression. 62
An improved method for liquid scintillation counting of 59Fe in ferrokinetic studies. 62
Expression of adhesion molecules and functional stimulation in human neutrophils: modulation by GM-CSF and role of the Bcr gene. 62
Policitemia vera. 62
Clinical relevance of murine double minute 2 single nucleotide polymorphisms 309 in familial myeloproliferative neoplasm. 62
Revised international prognostic scoring system for myelodysplastic syndromes 62
Genetic disorders of iron overload and the novel ''ferroportin disease'' 61
Hematologic passport for athletes competing in endurance sports: a feasibility study. 61
PRV-1 and its correlation with treatments and disease status in 210 patients with polycythemia vera and essential thrombocythemia 61
Pincered red cells and hereditary spherocytosis. 61
Sindrome anemica. 61
Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia 61
A rule-based expert system for automatic implementation of somatic variant clinical interpretation guidelines 61
Totale 6.971
Salva come PNG Salva come JPEG
Categoria #
all - tutte 108.691
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 108.691
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.395 0 0 0 0 0 316 74 356 30 468 145 6
2020/20212.860 335 257 76 300 7 378 31 453 126 439 374 84
2021/20222.194 32 8 67 39 101 130 40 119 120 93 341 1.104
2022/20236.374 745 374 48 520 634 706 3 404 2.642 33 165 100
2023/20242.279 254 448 96 207 220 623 65 137 15 53 60 101
2024/20251.409 156 569 173 188 109 214 0 0 0 0 0 0
Totale 24.683